Brian Piekos, Chief Financial Officer at KalVista Pharmaceuticals, Inc. (KALV), sold 1,862 shares at $20.22 ($38K) on 2026-04-17, disclosed to the SEC on 2026-04-20.
Open-market sale of $38k KALV by Chief Financial Officer. Not flagged as scheduled, tax-driven, or recurring — but no specific bearish signal from our filters. Reasons for insider sales vary widely.
Something here stands out, but not much.
| Filing → |
| KALV | SELL | 2025-11-26 | $120K | — | Filing → |
| GMTX | BUY | 2021-05-18 | $145K | — | Filing → |